Table 1.
Patient characteristics
|
Categorical characteristic |
3DCRT
n = 115
|
IG-IMRT
n = 388
|
P value |
|---|---|---|---|
| No patients (%) | No patients (%) | ||
| Performance status |
|
|
0.180 |
| 0 |
110 (96) |
367 (95) |
|
| 1 |
5 (4) |
21 (5) |
|
| Comorbidity* |
|
|
0.070 |
| Yes |
66 (60) |
215 (56) |
|
| No |
44 (40) |
166 (44) |
|
| Smoking# |
|
|
0.091 |
| Yes |
30 (32) |
106 (29) |
|
| No |
65 (68) |
255 (71) |
|
| T-stage |
|
|
0.190 |
| ≤T2a |
19 (17) |
96 (25) |
|
| T2b |
3 (2) |
10 (2) |
|
| ≥T2c |
92 (81) |
281 (73) |
|
| Gleason score |
|
|
<0.001 |
| 5-6 |
42 (44) |
49 (13) |
|
| 7 |
21 (22) |
197 (51) |
|
| 8-10 |
33 (34) |
141 (36) |
|
| Adjuvant ADT |
|
|
0.019 |
| Yes |
72 (88) |
350 (95) |
|
| No |
10 (12) |
20 (5) |
|
| Type of ADT |
|
|
0.054 |
| GnRH agonist |
100 (89) |
365 (95) |
|
| Antiandrogen |
12 (11) |
21 (5) |
|
|
Continuous characteristic |
Median (range) |
Median (range) |
P value |
| Age (y) |
63 (52–75) |
66 (49–76) |
<0.001 |
| PSA (ng/ml) |
32.7 (4.2-150) |
24.9 (4.2-200) |
<0.001 |
| PPB† (%) |
75 (17–100) |
67 (5–100) |
0.006 |
| Follow-up (yr) | 8.2 (0.1-12.5) | 3.5 (0.3-7.1) | <0.001 |
*Any comorbidity at the time of diagnosis.
#Smoking at the time of diagnosis.
†Percentage of positive (malignant) biopsies.